Serenity's Lead Therapeutic: SER-101

From our StressTek™ platform, we've identified SER-101 as our top therapeutic candidate for SLE. 

In SLE, antigen presenting cells (APCs) mis-recognize self-antigens, activate auto-reactive Th17 and Th1 cells, which further activate B cells to produce anti-self antibodies. Immune complexes with self-antigens cause damage through inflammation in multiple organs.

SER-101 induces immune tolerance in antigen presenting cells thereby preventing damage caused by auto-reactive T cells and B cells.

Demonstrated in multiple pre-clinical models

SER-101's anti-inflammatory effects have been demonstrated in multiple pre-clinical models. In addition to Lupus, SER-101 has demonstrated potential benefit for multiple sclerosis, inflammatory bowel syndrome, and COPD.

Disease

Multiple Sclerosis 

Inflammatory Bowel Syndrome

Stroke 

Lupus 

COPD

Model

EAE 

DSS & TNBS-induced colitis

Filament occlusion 

MRL/MpJ-Fas 

Smoke induced

lpr

A Differentiated Mechanism

SER-101 has a multi-faceted mechanism to exert immune tolerance. The primary driver for inducing immune tolerance relies on innate and scavenger receptors found on APCs.

 

In APCs, we've observed up-regulation of a network of genes for immune tolerance, notable among them are PD-L1 and IL-10. Further, we detected the activation of CD25+FoxP3+ T cells when naive T cells are exposed to SER-101-treated dendritic cells (DCs).  

Disease State

SER-101

white_logo_transparent.png

151 Charles St. W Suite 199

Kitchener, Ontario

N2G 1H6

479 Jessie Street 

San Francisco, California 

94103

© 2020 by Serenity Bioworks

Menu

Contact 

twitter.png
linkdin.png

Updates

For our latest company news subscribe below